Digital Biology MarketSize, Share & Industry Analysis, 2026-2034By ComponentBy ApplicationBy TechnologyBy End UserBy Deployment ModeBy Biological Data TypeBy Therapeutic AreaBy Therapeutic ModalityBy Business Model
Full title & scope — all 9 axes with their segments
Digital Biology Market Size, Share & Industry Analysis, By Component (Software and Platforms, Services, Hardware and Instruments, Data and Content), By Application (Drug Discovery, Synthetic Biology, Precision Medicine, Clinical Diagnostics, Agricultural Biotechnology, Industrial Biotechnology), By Technology (Artificial Intelligence and Machine Learning, Computational Biology and Bioinformatics, Multi-Omics Analytics, Digital Twins and Biosimulation, Lab Automation and Robotics, Cloud and High-Performance Computing), By End User (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Healthcare Providers, Contract Research Organizations, Agricultural Companies), By Deployment Mode (Cloud-Based, On-Premises, Hybrid), By Biological Data Type (Genomic Data, Proteomic Data, Transcriptomic Data, Metabolomic Data, Imaging and Phenotypic Data, Clinical and Real-World Data), By Therapeutic Area (Oncology, Neurology, Infectious Diseases, Immunology and Inflammation, Rare and Genetic Diseases, Metabolic and Cardiovascular Diseases), By Therapeutic Modality (Small Molecules, Biologics and Antibodies, Cell and Gene Therapies, Nucleic Acid Therapeutics, Vaccines), By Business Model (Software Licensing and Subscription, Platform-as-a-Service, Fee-for-Service and Contract Research, Collaboration and Milestone-Based, Data Licensing), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.
- 01By ComponentSoftware and Platforms · Services · Hardware and Instruments
- 02By ApplicationDrug Discovery · Synthetic Biology · Precision Medicine
- 03By TechnologyArtificial Intelligence and Machine Learning · Computational Biology and Bioinformatics · Multi-Omics Analytics
- 04By End UserPharmaceutical Companies · Biotechnology Companies · Academic and Research Institutes
- 05By Deployment ModeCloud-Based · On-Premises · Hybrid
- 06By Biological Data TypeGenomic Data · Proteomic Data · Transcriptomic Data
- 07By Therapeutic AreaOncology · Neurology · Infectious Diseases
- 08By Therapeutic ModalitySmall Molecules · Biologics and Antibodies · Cell and Gene Therapies
- 09By Business ModelSoftware Licensing and Subscription · Platform-as-a-Service · Fee-for-Service and Contract Research
- 10By Region
Market Analysis & Outlook
Digital biology covers the software, data, instruments and services that apply computation to biological research and development, including machine learning, simulation, bioinformatics and automated laboratory systems. It takes the form of licensed and cloud-delivered platforms, hardware used to generate and process biological data, licensed datasets and contract analysis services. Buyers include pharmaceutical and biotechnology developers, academic institutes, healthcare providers, contract research organizations and agricultural and industrial biotechnology firms.
The global digital biology market is valued at USD 12 billion in 2025 and is set to reach USD 44.8 billion by 2034, a compound annual growth rate of 15.65% across the 2026-2034 forecast period. The study tracks the market across USD 5.25 billion in 2020, USD 10.15 billion in 2024, USD 14 billion in 2026 and USD 25.7 billion in 2030.
On the component axis, growth rates run from 13.59% for Hardware and Instruments up to 16.94% for Software and Platforms. Software and Platforms carries the volume: USD 4.56 billion and 38% of revenue in 2025, USD 18.82 billion and 42% in 2034. The lines gaining share are Software and Platforms and Data and Content. Services and Hardware and Instruments lose share without losing revenue.
The application split puts Drug Discovery first, at USD 4.32 billion and 36% of revenue in 2025, rising to USD 14.78 billion and 33% in 2034. Synthetic Biology grows faster at 20.34% against 14.64%, moving from 12% of revenue to 17% by 2034. It cuts the same total as the component axis from a different commercial angle, so revenue does not add across the two.
North America is the largest region at 42% of 2025 revenue, worth USD 5.04 billion and reaching USD 16.39 billion by 2034. Asia Pacific follows at 25.5%, moving from USD 3.06 billion to USD 14.25 billion, and Middle East and Africa is the smallest at 3.5%. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.
Coverage extends to five regions, four component lines and nine segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies, short of a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global digital biology market moves from USD 5.25 billion in 2020 to USD 12 billion in 2025 and USD 44.8 billion by 2034, the forecast period compounding at 15.65% a year.
- 38% of 2025 revenue sits in Software and Platforms (USD 4.56 billion) and it remains the largest component line in 2034 at USD 18.82 billion and 42%.
- The bull case puts 2034 revenue at USD 51 billion and the bear case at USD 34.5 billion, either side of the USD 44.8 billion base case, each with its own stated assumption in the full report.
- The largest region is North America, generating USD 5.04 billion in 2025 (42% of the global total) and USD 16.39 billion by 2034, ahead of Asia Pacific at 25.5%.
- 89.29% of North America's base-year revenue comes from the United States alone: USD 4.5 billion in 2025, rising to USD 14.6 billion by 2034, which is why it is that region's worked example.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.
Market Trends
Revenue Share, By component
Base year 2025Software and Platforms leads with 38.0% of component segment revenue.
Share of component segment revenue, most recent base year.
The global digital biology market is shaped over 2026-2034 by three measurable movements: a change in the component mix, a shift in where revenue sits geographically, and the 15.65% rate carrying the total.
None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.
Software and Platforms outpaces Hardware and Instruments. The widest spread on the component axis is between Software and Platforms at 16.94% and Hardware and Instruments at 13.59%. Software and Platforms takes its share of revenue from 38% to 42% while Hardware and Instruments gives up ground, from 20% to 17%. Neither contracts: USD 4.56 billion becomes USD 18.82 billion, USD 2.4 billion becomes USD 7.62 billion. What the spread decides is which of them a supplier's revenue is exposed to.
Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 25.5% of revenue in 2025 to 31.8% in 2034, worth USD 3.06 billion rising to USD 14.25 billion; Latin America moves from 4.5% of revenue in 2025 to 4.95% in 2034, worth USD 0.54 billion rising to USD 2.22 billion; Middle East and Africa moves from 3.5% of revenue in 2025 to 3.95% in 2034, worth USD 0.42 billion rising to USD 1.77 billion. Share moves off the others in turn: North America at 42% moving to 36.6%, Europe at 24.5% moving to 22.7%, each still growing in revenue terms. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.
Growth compounds at 15.65% without a step change. Fifteen years of revenue run USD 5.25 billion in 2020, USD 10.15 billion in 2024, USD 12 billion in 2025, USD 14 billion in 2026, USD 25.7 billion in 2030 and USD 44.8 billion in 2034. Against 17.98% through the historical period, the 15.65% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the component and regional axes, not by the headline rate.
Market Growth Factors
Growth is concentrated in Software and Platforms
Market Drivers
3- 01Growth is concentrated in Software and Platforms
At 16.94% against a market rate of 15.65%, Software and Platforms is the line pulling the average up: USD 4.56 billion to USD 18.82 billion, and 38% of revenue to 42%. Nothing else on the axis grows as fast (Hardware and Instruments manages 13.59%) so the blended 15.65% is carried by this one line instead of shared across them. That makes position on the component axis a growth decision, not a product one.
- 02Growth lands where the revenue already is
The largest regional base is North America: USD 5.04 billion in 2025 at 42% of the global total, USD 16.39 billion by 2034, still 36.6%. Behind it, Asia Pacific holds 25.5%; USD 3.06 billion rising to USD 14.25 billion. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03The trend is already in the record
USD 5.25 billion in 2020, USD 10.15 billion in 2024 and USD 12 billion in 2025: 17.98% compound growth before the forecast period even begins. The forecast period then runs at 15.65%, ending 2034 at USD 44.8 billion. Fifteen years of unbroken growth in the series means the forecast rests on a demonstrated trajectory, not a projected turnaround, and it is why the 15.65% rate is applied flat across the whole period instead of ramped through it.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Adoption of AI-driven drug discovery | High | +12.5 | High | High | Medium |
| 2 | Growth in multi-omics and real-world data | Medium-High | +8 | High | Medium | Medium |
| 3 | Shift to cloud and subscription platforms | Medium-High | +6.5 | High | Medium | Medium |
| 4 | Synthetic biology and bioindustrial demand | Medium | +5 | Medium | Medium | High |
| 5 | Regulatory acceptance of in silico evidence | Medium | +3.5 | Low | Medium | High |
| 6 | Others | Low | +2.5 | Low | Low | Low |
| Total | +38 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Data quality, privacy and sharing limits | Medium-High | −2.2 | High | Medium | Medium |
| 2 | Shortage of computational biology talent and high compute cost | Medium | −1.7 | Medium | Medium | Low |
| 3 | Limited validation and reproducibility of model outputs | Medium | −1.3 | Medium | Medium | Low |
| Total | −5.2 | |||||
Drivers contribute 38 USD Billion and restraints remove 5.2 USD Billion, a net 32.8 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Growth in the global digital biology market comes from three measurable sources over 2026-2034: the market's own compounding at 15.65%, the share gained by faster-growing component lines, and expansion in the regions taking a larger part of global revenue.
Restraining Factors
What holds the forecast back
Market Restraints
2- 01What holds the forecast back
Where the forecast could miss: biotech funding stays tight, validation of model outputs lags and data privacy rules limit data sharing, so buyers delay platform spending and consolidate vendors. That path reaches USD 34.5 billion by 2034 instead of USD 44.8 billion, off an unchanged USD 12 billion in 2025.
- 02The largest line is not the fastest
With 30% of 2025 revenue (USD 3.6 billion) Services is where most of the market sits, and it grows at only 14.75% against the market's 15.65%. Revenue still reaches USD 12.54 billion by 2034 and share still falls to 28%: a drag on the average, not a decline.
Market Opportunities
Upside case: USD 51 billion by 2034
Market Opportunities
2- 01Upside case: USD 51 billion by 2034
Faster uptake of AI-designed candidates in clinical pipelines, wider regulatory acceptance of simulated evidence and falling compute costs extend platform adoption beyond large pharmaceutical buyers. On that assumption the market reaches USD 51 billion by 2034 against USD 44.8 billion in the base case, from the same USD 12 billion in 2025.
- 02The opening is on the component axis, not the regional one
Share on the component axis moves toward Software and Platforms, from 38% in 2025 to 42% in 2034, on 16.94% growth against the market's 15.65% and revenue rising from USD 4.56 billion to USD 18.82 billion. Taking position there does not require displacing whoever holds Software and Platforms, which is the harder and more expensive fight.
Market Challenges
Concentration on the component axis
Market Challenges
2- 01Concentration on the component axis
USD 4.56 billion of 2025 revenue sits in Software and Platforms, 38% of the total, and it is still 42% at USD 18.82 billion nine years later. No other single change on the component axis moves the total as much as a change in demand for that one line.
- 02North America is largely the United States
89.29% of the leading region is one country: the United States, at USD 4.5 billion against North America's USD 5.04 billion in 2025, and USD 14.6 billion by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
9 axesnine segmentation axes are reported; by component, by application, technology, end user, deployment mode, biological data type, therapeutic area, therapeutic modality and business model. They are alternative readings of one revenue pool, not parts that sum to it.
There are four lines on the component axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: two gain it, the rest give it up.
By Component · 4 segments
Software and Platforms Both Leads the Component Axis and Grows Fastest on It
- Largest Software and Platforms · 38%
- Fastest Software and Platforms · 16.9%
- Moves most Software and Platforms · +4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Software and Platforms | $4.56B | 38% | $18.82B | 42%+4 | 16.9% |
| Services | $3.60B | 30% | $12.54B | 28%-2 | 14.8% |
| Hardware and Instruments | $2.40B | 20% | $7.62B | 17%-3 | 13.6% |
| Data and Content | $1.44B | 12% | $5.82B | 13%+1 | 16.6% |
Software and platforms lead because they carry recurring subscription revenue and sit at the centre of every computational workflow, with hardware and services built around them. They also grow fastest, as buyers move from one-off projects to licensed, cloud-delivered tools, while data and content expand from a smaller base as proprietary datasets gain pricing power. The order does not change: Software and Platforms is still largest in 2034, and what moves is how much it holds. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Application · 6 segments
Drug Discovery Led by Application in 2025, with Synthetic Biology Growing Fastest
- Largest Drug Discovery · 36%
- Fastest Synthetic Biology · 20.3%
- Moves most Synthetic Biology · +5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Drug Discovery | $4.32B | 36% | $14.78B | 33%-3 | 14.6% |
| Synthetic Biology | $1.44B | 12% | $7.62B | 17%+5 | 20.3% |
| Precision Medicine | $2.16B | 18% | $8.51B | 19%+1 | 16.5% |
| Clinical Diagnostics | $1.92B | 16% | $6.27B | 14%-2 | 14.1% |
| Agricultural Biotechnology | $0.96B | 8% | $3.14B | 7%-1 | 14.1% |
| Industrial Biotechnology | $1.20B | 10% | $4.48B | 10% | 15.8% |
Drug discovery leads because pharmaceutical pipelines are the largest and most established buyers of computational biology, with budgets tied to target identification and candidate screening. Synthetic biology grows fastest, from a small base, as design, simulation and automation tools move from research groups into commercial strain and product development. By 2034 Drug Discovery is still ahead, making this a shift in weight, not a change of leader.
By Technology · 6 segments
Digital Twins and Biosimulation Outpaces the Axis While Artificial Intelligence and Machine Learning Holds the Largest Share
- Largest Artificial Intelligence and Machine Learning · 24%
- Fastest Digital Twins and Biosimulation · 21.1%
- Moves most Artificial Intelligence and Machine Learning · +6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Artificial Intelligence and Machine Learning | $2.88B | 24% | $13.44B | 30%+6 | 18.7% |
| Computational Biology and Bioinformatics | $2.64B | 22% | $7.62B | 17%-5 | 12.5% |
| Multi-Omics Analytics | $2.16B | 18% | $7.62B | 17%-1 | 15% |
| Digital Twins and Biosimulation | $0.96B | 8% | $5.38B | 12%+4 | 21.1% |
| Lab Automation and Robotics | $1.68B | 14% | $5.82B | 13%-1 | 14.8% |
| Cloud and High-Performance Computing | $1.68B | 14% | $4.92B | 11%-3 | 12.7% |
Artificial intelligence and machine learning lead because they are applied across target discovery, molecule design and image analysis, so almost every user type buys them. Digital twins and biosimulation grow fastest from a small base as developers use virtual models to reduce animal and early clinical testing and regulators become more open to simulated evidence. Artificial Intelligence and Machine Learning remains the largest line through 2034, so the axis changes in proportion, not in order.
By End User · 6 segments
Pharmaceutical Companies Led by End user in 2025, with Contract Research Organizations Growing Fastest
- Largest Pharmaceutical Companies · 34%
- Fastest Contract Research Organizations · 19.2%
- Moves most Pharmaceutical Companies · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmaceutical Companies | $4.08B | 34% | $13.90B | 31%-3 | 14.6% |
| Biotechnology Companies | $2.88B | 24% | $11.20B | 25%+1 | 16.3% |
| Academic and Research Institutes | $1.92B | 16% | $5.82B | 13%-3 | 13.1% |
| Healthcare Providers | $0.96B | 8% | $4.48B | 10%+2 | 18.7% |
| Contract Research Organizations | $1.20B | 10% | $5.82B | 13%+3 | 19.2% |
| Agricultural Companies | $0.96B | 8% | $3.58B | 8% | 15.8% |
Pharmaceutical companies lead because they hold the largest discovery budgets and the proprietary data that makes platforms useful. Contract research organizations grow fastest, from a smaller base, as sponsors outsource computational work and as these providers add in silico services to compete for early-stage programmes. Pharmaceutical Companies remains the largest line through 2034, so the axis changes in proportion, not in order.
By Deployment Mode · 3 segments
Cloud-Based Held the Dominant Share of the Deployment mode Segment in 2025
- Largest Cloud-Based · 52%
- Fastest Hybrid · 18.7%
- Moves most On-Premises · -8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Cloud-Based | $6.24B | 52% | $24.64B | 55%+3 | 16.5% |
| On-Premises | $3.36B | 28% | $8.96B | 20%-8 | 11.5% |
| Hybrid | $2.40B | 20% | $11.20B | 25%+5 | 18.7% |
Cloud-based delivery leads because it removes the cost of owning high-performance compute and lets teams scale during large screening and training runs. Hybrid deployment grows fastest as organizations with sensitive proprietary or patient data keep part of the workload local while using cloud capacity for peak demand. The order does not change: Cloud-Based is still largest in 2034, and what moves is how much it holds.
By Biological Data Type · 6 segments
Genomic Data Held the Dominant Share of the Biological data type Segment in 2025
- Largest Genomic Data · 32%
- Fastest Imaging and Phenotypic Data · 18.7%
- Moves most Genomic Data · -5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Genomic Data | $3.84B | 32% | $12.09B | 27%-5 | 13.6% |
| Proteomic Data | $1.68B | 14% | $7.17B | 16%+2 | 17.5% |
| Transcriptomic Data | $1.92B | 16% | $6.27B | 14%-2 | 14.1% |
| Metabolomic Data | $0.72B | 6% | $3.14B | 7%+1 | 17.8% |
| Imaging and Phenotypic Data | $1.44B | 12% | $6.72B | 15%+3 | 18.7% |
| Clinical and Real-World Data | $2.40B | 20% | $9.41B | 21%+1 | 16.4% |
Genomic data leads because sequencing is the longest established and most widely generated data type, and nearly every discovery and diagnostic workflow starts from it. Imaging and phenotypic data grow fastest, from a smaller base, as automated microscopy and high-content screening produce large volumes that machine learning can read. The order does not change: Genomic Data is still largest in 2034, and what moves is how much it holds.
By Therapeutic Area · 6 segments
Oncology Held the Dominant Share of the Therapeutic area Segment in 2025
- Largest Oncology · 34%
- Fastest Neurology · 17.5%
- Moves most Infectious Diseases · -4 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Oncology | $4.08B | 34% | $14.78B | 33%-1 | 15.4% |
| Neurology | $1.68B | 14% | $7.17B | 16%+2 | 17.5% |
| Infectious Diseases | $1.68B | 14% | $4.48B | 10%-4 | 11.5% |
| Immunology and Inflammation | $1.92B | 16% | $7.62B | 17%+1 | 16.6% |
| Rare and Genetic Diseases | $1.44B | 12% | $5.82B | 13%+1 | 16.8% |
| Metabolic and Cardiovascular Diseases | $1.20B | 10% | $4.93B | 11%+1 | 17% |
Oncology leads because tumour genomics, a crowded pipeline and clear biomarker-driven development make computational methods easy to justify. Neurology grows fastest as complex disease biology and high late-stage failure rates push developers toward modelling and multi-modal data to improve target choice. By 2034 Oncology is still ahead, making this a shift in weight, not a change of leader.
By Therapeutic Modality · 5 segments
Scale in Small Molecules and Growth in Cell and Gene Therapies Define the Therapeutic modality Axis
- Largest Small Molecules · 36%
- Fastest Cell and Gene Therapies · 22%
- Moves most Small Molecules · -6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Small Molecules | $4.32B | 36% | $13.44B | 30%-6 | 13.4% |
| Biologics and Antibodies | $3.84B | 32% | $13.89B | 31%-1 | 15.4% |
| Cell and Gene Therapies | $1.20B | 10% | $7.17B | 16%+6 | 22% |
| Nucleic Acid Therapeutics | $1.20B | 10% | $6.72B | 15%+5 | 21.1% |
| Vaccines | $1.44B | 12% | $3.58B | 8%-4 | 10.7% |
Small molecules lead because computational chemistry, docking and property prediction are the most mature uses of the technology and fit large existing compound libraries. Cell and gene therapies grow fastest from a small base as the design of vectors, editing tools and manufacturing processes increasingly relies on modelling and automation. Leadership changes hands: Biologics and Antibodies is the largest line by 2034, not Small Molecules.
By Business Model · 5 segments
Software Licensing and Subscription Held the Dominant Share of the Business model Segment in 2025
- Largest Software Licensing and Subscription · 30%
- Fastest Platform-as-a-Service · 19.5%
- Moves most Platform-as-a-Service · +6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Software Licensing and Subscription | $3.60B | 30% | $12.99B | 29%-1 | 15.3% |
| Platform-as-a-Service | $2.16B | 18% | $10.75B | 24%+6 | 19.5% |
| Fee-for-Service and Contract Research | $3.36B | 28% | $9.86B | 22%-6 | 12.7% |
| Collaboration and Milestone-Based | $1.68B | 14% | $6.27B | 14% | 15.8% |
| Data Licensing | $1.20B | 10% | $4.93B | 11%+1 | 17% |
Software licensing and subscription lead because recurring contracts are the established way platforms are sold to pharmaceutical and research buyers. Platform-as-a-service grows fastest as buyers want to call models and pipelines through interfaces and pay for use instead of buying fixed seats. By 2034 Software Licensing and Subscription is still ahead, making this a shift in weight, not a change of leader.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 5.4 points of share move elsewhere by 2034, while revenue still grows 3.3×.
- Rank 1 of 5
- 2025 share 42%
- By 2034 36.6%
- Revenue $5.04B → $16.39B
USD 5.04 billion of 2025 revenue is generated in North America, 42% of the global digital biology market with USD 16.39 billion projected for 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.
36.6% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The component mix reported at global level applies here, with Software and Platforms the largest line at 38% of 2025 revenue and Software and Platforms the fastest-growing at 16.94%. Revenue for North America is broken out by every segmentation axis and by country in the full report.
United States
Sets the pace for North America at 89.3% of it, growing 3.2×.
- In region 1 of 2
- Of region 89.3%
- Of global 37.5%
- Revenue $4.50B → $14.60B
The United States is the largest market within North America, generating USD 4.5 billion in 2025 and projected to reach USD 14.6 billion by 2034. Because it is 89.29% of the region in the base year, North America's totals move with this one country instead of a spread of them. The region itself runs USD 5.04 billion to USD 16.39 billion over the same period, and this is the market carrying the country-level detail in the full report.
the United States buys along the same lines as the market globally; Software and Platforms first at 38% of 2025 revenue and 42% in 2034, Software and Platforms fastest at 16.94% on a share moving from 38% to 42%. Its 89.29% weight in North America means those movements carry straight into the regional totals. Per-component revenue for the United States appears on its own in the full report.
Digital biology covers software, computational platforms and data services used in life science research, so most of it sits outside direct product licensing. Where a tool is marketed for clinical use, such as diagnostic interpretation or decision support, the Food and Drug Administration regulates it as software as a medical device and assigns a risk class that sets the premarket route: clearance, De Novo classification or approval. Research-use-only products must be labelled as such and cannot carry clinical claims. Suppliers handling patient genomic data also answer to the Health Insurance Portability and Accountability Act, and laboratory services fall under the Clinical Laboratory Improvement Amendments. Cybersecurity and quality system expectations apply to regulated software.
The suppliers tracked in this study (Thermo Fisher Scientific Inc., Illumina, Inc., Schrödinger, Inc., Certara, Inc., Dassault Systèmes SE, Insilico Medicine, Recursion Pharmaceuticals, Inc., Exscientia plc, Benchling, Inc., Agilent Technologies, Inc., QIAGEN N.V., Danaher Corporation, Revvity, Inc., Twist Bioscience Corporation, Ginkgo Bioworks Holdings, Inc., Simulations Plus, Inc., Absci Corporation, Evotec SE, Compugen Ltd., BenevolentAI, Genedata AG, Bio-Rad Laboratories, Inc., 10x Genomics, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, NVIDIA Corporation, Tempus AI, Inc., Dotmatics and Cellarity, Inc.) compete in the United States across the component lines above. Software and Platforms is where the volume is, at 38% of 2025 revenue, and it is growing fastest as well at 16.94%. Country-level shares and positioning per company sit in the full report.
Canada
2nd-largest in North America, growing 3.4×.
- In region 2 of 2
- Of region 7.9%
- Of global 3.3%
- Revenue $0.40B → $1.35B
Within North America, Canada accounts for 7.94% of regional revenue and 3.33% of the global total, worth USD 0.4 billion in 2025 and USD 1.35 billion by 2034.
Europe Market Analysis
The 3rd-largest region covered — 1.8 points of share move elsewhere by 2034, while revenue still grows 3.5×.
- Rank 3 of 5
- 2025 share 24.5%
- By 2034 22.7%
- Revenue $2.94B → $10.17B
In Europe, 24.5% of global revenue puts 2025 at USD 2.94 billion on the way to USD 10.17 billion by 2034. Among the five regions it ranks third by revenue in both years.
By 2034 the share stands at 22.7%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Within the region the component split tracks the global one; 38% of 2025 revenue in Software and Platforms, fastest growth of 16.94% in Software and Platforms. The full report breaks Europe out along every axis and by country.
United Kingdom
The largest market in Europe, growing 3.4×.
- In region 1 of 3
- Of region 23.1%
- Of global 5.7%
- Revenue $0.68B → $2.30B
The United Kingdom is the largest market within Europe, generating USD 0.68 billion in 2025 and projected to reach USD 2.3 billion by 2034. Its 23.13% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 2.94 billion and USD 10.17 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Composition here matches the global split: the largest line is Software and Platforms at 38% of 2025 revenue, easing to 42% by 2034, and the fastest is Software and Platforms at 16.94%, from 38% to 42%. Its 23.13% weight in Europe means those movements carry straight into the regional totals. The United Kingdom carries its own component breakdown in the full report.
In the United Kingdom, digital biology tools used purely for research face no dedicated product licence. Software with a clinical purpose is regulated by the Medicines and Healthcare products Regulatory Agency as a medical device, and suppliers must register with the agency and obtain the UK Conformity Assessed mark, with some products still relying on the CE mark under transitional arrangements. Risk classification determines whether an approved body must assess the file. Quality management and software lifecycle standards are expected as evidence of conformity. Handling of genomic and health data is governed by the UK General Data Protection Regulation and the Data Protection Act, enforced by the Information Commissioner's Office, and genetic work may also involve the Human Tissue Authority.
In the United Kingdom the field is Thermo Fisher Scientific Inc., Illumina, Inc., Schrödinger, Inc., Certara, Inc., Dassault Systèmes SE, Insilico Medicine, Recursion Pharmaceuticals, Inc., Exscientia plc, Benchling, Inc., Agilent Technologies, Inc., QIAGEN N.V., Danaher Corporation, Revvity, Inc., Twist Bioscience Corporation, Ginkgo Bioworks Holdings, Inc., Simulations Plus, Inc., Absci Corporation, Evotec SE, Compugen Ltd., BenevolentAI, Genedata AG, Bio-Rad Laboratories, Inc., 10x Genomics, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, NVIDIA Corporation, Tempus AI, Inc., Dotmatics and Cellarity, Inc.. Volume and growth sit in the same line, Software and Platforms, at 38% of 2025 revenue and 16.94% growth. The commercial size of that position is USD 2.94 billion in 2025 and USD 10.17 billion by 2034, 24.5% of the global total in the base year.
Germany
2nd-largest in Europe, growing 3.5×.
- In region 2 of 3
- Of region 21.1%
- Of global 5.2%
- Revenue $0.62B → $2.20B
Germany is sized at USD 0.62 billion in 2025, rising to USD 2.2 billion by 2034; 5.17% of global revenue and 21.09% of Europe. It is reported separately from the United Kingdom across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 3.5×.
- In region 3 of 3
- Of region 13.6%
- Of global 3.3%
- Revenue $0.40B → $1.40B
Within Europe, France accounts for 13.61% of regional revenue and 3.33% of the global total, worth USD 0.4 billion in 2025 and USD 1.4 billion by 2034.
Asia Pacific Market Analysis
The 2nd-largest region covered, and the one gaining the most — it picks up 6.3 points of share by 2034, while revenue still grows 4.7×.
- Rank 2 of 5
- 2025 share 25.5%
- By 2034 31.8%
- Revenue $3.06B → $14.25B
USD 3.06 billion of 2025 revenue is generated in Asia Pacific, 25.5% of the global digital biology market and reaches USD 14.25 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
31.8% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 15.65% global rate, so this region warrants separate treatment and should not be scaled off the total.
The component mix reported at global level applies here, with Software and Platforms the largest line at 38% of 2025 revenue and Software and Platforms the fastest-growing at 16.94%. The full report breaks Asia Pacific out along every axis and by country.
China
The largest market in Asia Pacific, growing 5.2×.
- In region 1 of 3
- Of region 31.1%
- Of global 7.9%
- Revenue $0.95B → $4.90B
USD 0.95 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 4.9 billion by 2034. Its 31.05% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Set against USD 3.06 billion and USD 14.25 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
China buys along the same lines as the market globally; Software and Platforms first at 38% of 2025 revenue and 42% in 2034, Software and Platforms fastest at 16.94% on a share moving from 38% to 42%. With 31.05% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by component for China is reported separately in the full report.
In China, the National Medical Products Administration regulates digital biology products that have a medical purpose, including diagnostic software and artificial intelligence based analysis tools, which are classified by risk and must be registered before sale, often with local clinical evaluation and testing. Research platforms are not subject to the same registration. Human genetic resources are tightly controlled: the Ministry of Science and Technology administers rules on collection, storage and cross-border transfer of genetic material and related data, and foreign suppliers usually work through local partners. The Personal Information Protection Law, the Data Security Law and the Cybersecurity Law add obligations on data localisation, consent and export assessment.
Thermo Fisher Scientific Inc., Illumina, Inc., Schrödinger, Inc., Certara, Inc., Dassault Systèmes SE, Insilico Medicine, Recursion Pharmaceuticals, Inc., Exscientia plc, Benchling, Inc., Agilent Technologies, Inc., QIAGEN N.V., Danaher Corporation, Revvity, Inc., Twist Bioscience Corporation, Ginkgo Bioworks Holdings, Inc., Simulations Plus, Inc., Absci Corporation, Evotec SE, Compugen Ltd., BenevolentAI, Genedata AG, Bio-Rad Laboratories, Inc., 10x Genomics, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, NVIDIA Corporation, Tempus AI, Inc., Dotmatics and Cellarity, Inc. are the suppliers covered in China. Software and Platforms is both the largest line, at 38% of 2025 revenue, and the fastest-growing at 16.94%. A supplier weighted toward Asia Pacific is competing over a base of USD 3.06 billion in 2025, reaching USD 14.25 billion by 2034 on the trajectory this study models.
Japan
2nd-largest in Asia Pacific, growing 3.7×.
- In region 2 of 3
- Of region 22.9%
- Of global 5.8%
- Revenue $0.70B → $2.60B
5.83% of global revenue is generated in Japan; USD 0.7 billion in 2025, reaching USD 2.6 billion in 2034, and 22.88% of Asia Pacific.
India
3rd-largest in Asia Pacific, growing 6.3×.
- In region 3 of 3
- Of region 11.4%
- Of global 2.9%
- Revenue $0.35B → $2.20B
Within Asia Pacific, India accounts for 11.44% of regional revenue and 2.92% of the global total, worth USD 0.35 billion in 2025 and USD 2.2 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered — it picks up 0.5 points of share by 2034, while revenue still grows 4.1×.
- Rank 4 of 5
- 2025 share 4.5%
- By 2034 5%
- Revenue $0.54B → $2.22B
Latin America holds 4.5% of the global digital biology market in 2025, worth USD 0.54 billion with USD 2.22 billion projected for 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.
4.95% of global revenue sits here by 2034, up from the 2025 level, on growth above the market's own 15.65%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Within the region the component split tracks the global one; 38% of 2025 revenue in Software and Platforms, fastest growth of 16.94% in Software and Platforms. Per-axis and per-country detail for Latin America sits in the full report.
Brazil
The largest market in Latin America, growing 4.2×.
- In region 1 of 2
- Of region 44.4%
- Of global 2%
- Revenue $0.24B → $1B
44.44% of Latin America's base-year revenue comes from Brazil; USD 0.24 billion, rising to USD 1 billion by 2034. Its 44.44% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Set against USD 0.54 billion and USD 2.22 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Demand in Brazil follows the component mix reported at global level: Software and Platforms is the largest line at 38% of 2025 revenue, moving to 42% by 2034, while Software and Platforms grows fastest at 16.94% and takes its share from 38% to 42%. Since 44.44% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by component for Brazil is reported separately in the full report.
In Brazil, the National Health Surveillance Agency, known as ANVISA, regulates digital biology products intended for diagnosis or other medical use, treating qualifying software as a health product that must be classified by risk and registered or notified before it can be marketed. A local registration holder is required for foreign suppliers, and manufacturers generally need to demonstrate good manufacturing practice certification. Labelling must appear in Portuguese. Research tools without a clinical claim fall outside this route. Genetic heritage and associated knowledge are covered by national biodiversity legislation administered through the SisGen system, and personal and genetic data are governed by the General Data Protection Law, enforced by the national data protection authority.
In Brazil the field is Thermo Fisher Scientific Inc., Illumina, Inc., Schrödinger, Inc., Certara, Inc., Dassault Systèmes SE, Insilico Medicine, Recursion Pharmaceuticals, Inc., Exscientia plc, Benchling, Inc., Agilent Technologies, Inc., QIAGEN N.V., Danaher Corporation, Revvity, Inc., Twist Bioscience Corporation, Ginkgo Bioworks Holdings, Inc., Simulations Plus, Inc., Absci Corporation, Evotec SE, Compugen Ltd., BenevolentAI, Genedata AG, Bio-Rad Laboratories, Inc., 10x Genomics, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, NVIDIA Corporation, Tempus AI, Inc., Dotmatics and Cellarity, Inc.. Software and Platforms is where the volume is, at 38% of 2025 revenue, and it is growing fastest as well at 16.94%. The commercial size of that position is USD 0.54 billion in 2025 and USD 2.22 billion by 2034, 4.5% of the global total in the base year.
Mexico
2nd-largest in Latin America, growing 4.4×.
- In region 2 of 2
- Of region 20.4%
- Of global 0.9%
- Revenue $0.11B → $0.48B
Mexico is sized at USD 0.11 billion in 2025, rising to USD 0.48 billion by 2034; 0.92% of global revenue and 20.37% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 0.5 points of share by 2034, while revenue still grows 4.2×.
- Rank 5 of 5
- 2025 share 3.5%
- By 2034 4%
- Revenue $0.42B → $1.77B
USD 0.42 billion of 2025 revenue is generated in Middle East and Africa, 3.5% of the global digital biology market rising to USD 1.77 billion in 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.
By 2034 the share has moved up to 3.95%, because it outgrows the market's 15.65%; the revenue added here is disproportionate to where the region started.
Segment composition follows the global pattern: Software and Platforms largest at 38% of 2025 revenue, Software and Platforms fastest at 16.94%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
Israel
The largest market in Middle East and Africa, growing 4.6×.
- In region 1 of 2
- Of region 28.6%
- Of global 1%
- Revenue $0.12B → $0.55B
28.57% of Middle East and Africa's base-year revenue comes from Israel; USD 0.12 billion, rising to USD 0.55 billion by 2034. It accounts for 28.57% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 0.42 billion in 2025 and USD 1.77 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Composition here matches the global split: the largest line is Software and Platforms at 38% of 2025 revenue, easing to 42% by 2034, and the fastest is Software and Platforms at 16.94%, from 38% to 42%. Its 28.57% weight in Middle East and Africa means those movements carry straight into the regional totals. Israel carries its own component breakdown in the full report.
In Israel, the Ministry of Health, through its medical device division within the Israel Medical Devices Registry, regulates digital biology software that is intended for clinical use. Such products are classified by risk and must be listed in the Registry through a local authorised representative before sale, usually relying on approval from a recognised foreign authority such as the Food and Drug Administration or a European notified body. Labelling is expected in Hebrew, with English or Arabic accepted in some cases. Research-use tools do not require listing. Genetic information is subject to the Genetic Information Law, and personal data handling falls under the Protection of Privacy Law, supervised by the Privacy Protection Authority.
In Israel the field is Thermo Fisher Scientific Inc., Illumina, Inc., Schrödinger, Inc., Certara, Inc., Dassault Systèmes SE, Insilico Medicine, Recursion Pharmaceuticals, Inc., Exscientia plc, Benchling, Inc., Agilent Technologies, Inc., QIAGEN N.V., Danaher Corporation, Revvity, Inc., Twist Bioscience Corporation, Ginkgo Bioworks Holdings, Inc., Simulations Plus, Inc., Absci Corporation, Evotec SE, Compugen Ltd., BenevolentAI, Genedata AG, Bio-Rad Laboratories, Inc., 10x Genomics, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, NVIDIA Corporation, Tempus AI, Inc., Dotmatics and Cellarity, Inc.. Software and Platforms is both the largest line, at 38% of 2025 revenue, and the fastest-growing at 16.94%. The commercial size of that position is USD 0.42 billion in 2025, moving to USD 1.77 billion by 2034 across the forecast period.
United Arab Emirates
2nd-largest in Middle East and Africa, growing 5.7×.
- In region 2 of 2
- Of region 16.7%
- Of global 0.6%
- Revenue $0.07B → $0.40B
Within Middle East and Africa, the United Arab Emirates accounts for 16.67% of regional revenue and 0.58% of the global total, worth USD 0.07 billion in 2025 and USD 0.4 billion by 2034.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by component, application, technology, end user, deployment mode, biological data type, therapeutic area, therapeutic modality, business model, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Software and Platforms Volume and Software and Platforms Momentum
The study covers the following suppliers: Thermo Fisher Scientific Inc., Illumina, Inc., Schrödinger, Inc., Certara, Inc., Dassault Systèmes SE, Insilico Medicine, Recursion Pharmaceuticals, Inc., Exscientia plc, Benchling, Inc., Agilent Technologies, Inc., QIAGEN N.V., Danaher Corporation, Revvity, Inc., Twist Bioscience Corporation, Ginkgo Bioworks Holdings, Inc., Simulations Plus, Inc., Absci Corporation, Evotec SE, Compugen Ltd., BenevolentAI, Genedata AG, Bio-Rad Laboratories, Inc., 10x Genomics, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, NVIDIA Corporation, Tempus AI, Inc., Dotmatics and Cellarity, Inc..
The competitive line that matters is the component one, not the geographic one. Software and Platforms is 38% of 2025 revenue at USD 4.56 billion and still 42% in 2034, so it is where the volume sits and where an incumbent's position is hardest to move. Movement is concentrated in Software and Platforms; 16.94% growth, against 13.59% at the other end of the axis in Hardware and Instruments. A supplier positioned in one is not automatically positioned in the other, so a field of this size stays viable in a market of USD 12 billion.
Suppliers in this market are separated by the breadth of proprietary biological data they hold, the accuracy of models that have been validated against laboratory results, and the ability to integrate with the instruments and data systems buyers already run. The largest players hold broad portfolios, installed instrument bases, large compute access and long customer relationships, which lets them bundle software with hardware and services. Smaller and venture-backed suppliers compete on narrow technical depth in a single modality or task, speed of iteration and flexible commercial terms, and often partner with larger firms for distribution and data access.
Geographic reach is the other axis of competition. North America alone accounts for 42% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Asia Pacific adds a further 25.5%.
Profiles, financials, shares and development histories for each company sit in the full report; this summary carries the structure only.
List of Key Digital Biology Market Companies Profiled
29 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Thermo Fisher Scientific Inc.(United States)
- Illumina, Inc.(United States)
- Schrödinger, Inc.(United States)
- Certara, Inc.(United States)
- Dassault Systèmes SE(France)
- Insilico Medicine(Hong Kong)
- Recursion Pharmaceuticals, Inc.(United States)
- Exscientia plc(United Kingdom)
- Benchling, Inc.(United States)
- Agilent Technologies, Inc.(United States)
- QIAGEN N.V.(Netherlands)
- Danaher Corporation(United States)
- Revvity, Inc.(United States)
- Twist Bioscience Corporation(United States)
- Ginkgo Bioworks Holdings, Inc.(United States)
- Simulations Plus, Inc.(United States)
- Absci Corporation(United States)
- Evotec SE(Germany)
- Compugen Ltd.(Israel)
- BenevolentAI(United Kingdom)
- Genedata AG(Switzerland)
- Bio-Rad Laboratories, Inc.(United States)
- 10x Genomics, Inc.(United States)
- Pacific Biosciences of California, Inc.(United States)
- Oxford Nanopore Technologies plc(United Kingdom)
- NVIDIA Corporation(United States)
- Tempus AI, Inc.(United States)
- Dotmatics(United States)
- Cellarity, Inc.(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 9 axes (Component, Application, Technology, End User, Deployment Mode, Biological Data Type, Therapeutic Area, Therapeutic Modality, Business Model), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 29 key companies, and the research methodology behind every estimate.
Segmentation
9 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Digital Biology Market projected to reach?
USD 44.8 USD Billion by 2034, CAGR 15.65%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 42% of global revenue through 2034.
05Which segment leads the market?
Software and Platforms is the largest line by component, at 38% of revenue in 2025.
06Who are the key companies profiled?
Thermo Fisher Scientific Inc., Illumina, Inc., Schrödinger, Inc., Certara, Inc., Dassault Systèmes SE, Insilico Medicine, Recursion Pharmaceuticals, Inc., Exscientia plc, Benchling, Inc., Agilent Technologies, Inc., QIAGEN N.V., Danaher Corporation, Revvity, Inc., Twist Bioscience Corporation, Ginkgo Bioworks Holdings, Inc., Simulations Plus, Inc., Absci Corporation, Evotec SE, Compugen Ltd., BenevolentAI, Genedata AG, Bio-Rad Laboratories, Inc., 10x Genomics, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, NVIDIA Corporation, Tempus AI, Inc., Dotmatics, Cellarity, Inc.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.